Long-term effects of progestins on bone quality and fractures.
The effects of progestins on the quality of bone and their influence on the risk of fractures are reviewed. Data discussed are based on experimental studies in vivo that generally lasted for longer than one year. Information is given on the background of osteoporosis and on several means of inducing changes in bone quality. In young women who start using oral contraceptives based on progestins alone shortly after pubertal development, a significant decrease in bone quality has been documented. World Health Organization experts have concluded that this is not a real argument for restrictions on the use of these contraceptives. In postmenopausal women, no evidence has been found for a bone-protective or an estrogen-antagonistic effect of progestins. A wide range of estrogens have been used that have shown positive effects on bone, which are not antagonized by progestins. The therapeutic use of high-dose megestrol acetate may result in marked negative effects on bone, leading to severe osteoporosis, possibly due to the inherent glucocorticoid activity of this progestin. Other pharmacotherapeutic agents that can be used in postmenopausal therapy, and that clearly have beneficial effects on bone, are discussed.
Thijssen
Jos H H
JH
University Medical Centre Utrecht, Utrecht, The Netherlands. J.Thijssen@umcutrecht.nl
D015519:Bone Density / Q000187:drug effects; D001861:Bone Regeneration / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003276:Contraceptives, Oral / Q000008:administration & dosage; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D020249:Hormone Replacement Therapy; D006801:Humans; D010024:Osteoporosis / Q000150:complications; D011372:Progestins / Q000008:administration & dosage*
D003276:Contraceptives, Oral; D011372:Progestins